Movers and SHAKERS
Tuesday, January 28, 2020
Emerging as a Leader in Race to Develop KRAS Inhibitor
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company's clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Cosme Ordonez, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations...
Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. All five evaluable patients showed tumor regression (100% response), clinical benefit and a reduction in mutated KRAS burden. Five different KRAS mutations were targeted by onvansertib, which accounts for more than 90% of all...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.